Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SLP 
Simulations Plus Inc (SLP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: SLP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $25.33
1 Year Target Price $25.33
| 5 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -44.7% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 302.91M USD | Price to earnings Ratio - | 1Y Target Price 25.33 |
Price to earnings Ratio - | 1Y Target Price 25.33 | ||
Volume (30-day avg) 6 | Beta 0.85 | 52 Weeks Range 12.39 - 37.67 | Updated Date 09/14/2025 |
52 Weeks Range 12.39 - 37.67 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.15 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -78.62% | Operating Margin (TTM) 18.15% |
Management Effectiveness
Return on Assets (TTM) 2.74% | Return on Equity (TTM) -41.49% |
Valuation
Trailing PE - | Forward PE 52.91 | Enterprise Value 275182005 | Price to Sales(TTM) 3.77 |
Enterprise Value 275182005 | Price to Sales(TTM) 3.77 | ||
Enterprise Value to Revenue 3.42 | Enterprise Value to EBITDA 20.02 | Shares Outstanding 20127100 | Shares Floating 16618552 |
Shares Outstanding 20127100 | Shares Floating 16618552 | ||
Percent Insiders 17.38 | Percent Institutions 85.61 |
Upturn AI SWOT
Simulations Plus Inc
Company Overview
History and Background
Simulations Plus, Inc. was founded in 1996. It has grown through organic expansion and strategic acquisitions, focusing on simulation and modeling software for pharmaceutical, biotechnology, and chemical industries.
Core Business Areas
- Software Solutions: Develops and sells simulation software for drug discovery, development, and regulatory submissions.
- Consulting Services: Provides consulting services related to modeling and simulation, including training and custom modeling projects.
- ADMET Predictor: Machine-learning-based software platform for early-stage drug discovery and development, predicting Absorption, Distribution, Metabolism, Excretion, and Toxicity properties.
Leadership and Structure
Shawn O'Connor serves as the CEO. The company has a board of directors and a management team leading various functional areas like sales, marketing, R&D, and finance.
Top Products and Market Share
Key Offerings
- GastroPlus: Physiologically-based biopharmaceutics (PBBM) modeling software used to simulate drug absorption and pharmacokinetics. Estimates vary, but it's a leading product in its niche, accounting for significant revenue. Competitors include Certara Simcyp and Open Systems Pharmacology (freeware). Revenue from this product is proprietary.
- Market Share: A leading software. Estimates vary but is a leading solution in its niche. Exact percentage is not publicly available.
- ADMET Predictor: Machine-learning-based software for predicting drug properties. The product contributes a substantial percentage of company revenue. Market share estimates vary. Competitors include Schrodinger and Dotmatics. Revenue from this product is proprietary.
- Market Share: The product contributes a substantial percentage of company revenue. Market share estimates vary. Exact percentage is not publicly available.
- DDDPlus: Provides computational solutions for in vitro dissolution testing. Competitors include Pharsight, Genedata, and Insightful Science. Revenue from this product is proprietary.
- Market Share: DDDPlus is a niche product and does not account for a great market share overall. Exact percentage is not publicly available.
Market Dynamics
Industry Overview
The pharmaceutical software market is growing, driven by increased R&D spending, regulatory requirements, and the need for faster drug development. The industry involves software and services for simulating various aspects of drug behavior in the body.
Positioning
Simulations Plus is positioned as a leading provider of simulation and modeling software for the pharmaceutical industry, with a strong focus on physiologically-based pharmacokinetics (PBPK) and ADMET prediction.
Total Addressable Market (TAM)
The global pharmaceutical software market is estimated at multi-billion USD. Simulations Plus is well-positioned to capture a portion of this market through its specialized software and services.
Upturn SWOT Analysis
Strengths
- Strong domain expertise in pharmaceutical modeling and simulation
- Established reputation and customer base
- Proprietary software and algorithms
- Recurring revenue model
- High-quality products and reputation among researchers and regulators
Weaknesses
- Reliance on specific software products
- Potential competition from larger software companies
- Limited marketing resources compared to larger competitors
- Vulnerability to rapid technological changes
Opportunities
- Expanding into new applications (e.g., cosmetics, food)
- Growing demand for simulation software due to increased R&D spending
- Partnerships with pharmaceutical companies and CROs
- Geographic expansion
- Further enhance AI/ML capabilities within its software
Threats
- Competition from open-source software
- Economic downturns impacting pharmaceutical R&D budgets
- Changes in regulatory requirements
- Emergence of disruptive technologies
- Intellectual property infringement
Competitors and Market Share
Key Competitors
- Certara (CERT)
- Schru00f6dinger (SDGR)
- Open Systems Pharmacology (No Public Symbol)
Competitive Landscape
Simulations Plus has a competitive advantage in certain areas of pharmaceutical simulation, particularly PBPK and ADMET prediction. However, larger companies like Certara and Schru00f6dinger have broader product portfolios and greater resources. Open Systems Pharmacology is the main non-commercial competition which offers free software.
Major Acquisitions
Cognigen Corporation
- Year: 2015
- Acquisition Price (USD millions): 34.3
- Strategic Rationale: Expanded Simulations Plus's consulting services and expertise in pharmacometrics.
DILIsym Services, Inc.
- Year: 2017
- Acquisition Price (USD millions): 11.8
- Strategic Rationale: Added expertise in drug-induced liver injury (DILI) modeling and simulation.
Growth Trajectory and Initiatives
Historical Growth: Simulations Plus has experienced steady revenue growth driven by increased adoption of its software and services. Acquisitions have also contributed to growth.
Future Projections: Analyst estimates suggest continued growth in the pharmaceutical software market, which Simulations Plus is well-positioned to capitalize on. Projections depend on economic and market conditions.
Recent Initiatives: Recent initiatives include new software releases, partnerships, and geographic expansion efforts.
Summary
Simulations Plus is a moderately strong company that provides specialized software solutions for the pharmaceutical industry. Its strong expertise in niche areas, along with a recurring revenue model, supports stable growth. However, competition from larger players and the risk of technological change must be monitored. Recent acquisitions and initiatives demonstrate proactive expansion efforts.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is based on estimations and may vary. Investment decisions should be made based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Simulations Plus Inc
Exchange NASDAQ | Headquaters Research Triangle Park, NC, United States | ||
IPO Launch date 1997-06-18 | CEO - | ||
Sector Healthcare | Industry Health Information Services | Full time employees 243 | Website https://www.simulations-plus.com |
Full time employees 243 | Website https://www.simulations-plus.com | ||
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.